Journal of Clinical Oncology, Vol 12, 2060-2065, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study

FL Meyskens Jr, PY Liu, RJ Tuthill, VK Sondak, WS Fletcher, WR Jewell, W Samlowski, SP Balcerzak, DJ Rector and RD Noyes
University of California, Irvine, Orange.

PURPOSE: A national cooperative group trial was conducted in patients with early-stage cutaneous malignant melanoma to determine if oral vitamin A can increase disease-free survival or survival. PATIENTS AND METHODS: Two hundred forty-eight patients with completely resected melanoma of Breslow's thickness greater than 0.75 mm and clinically negative lymph nodes were randomized to oral vitamin A (100,000 IU/d) for 18 months or to observation. Patients were stratified by Breslow's thickness of primary lesion (0.76 to 1.50 mm, 1.51 to 3.00 mm, or > 3.00 mm), sex, and type of therapy (excision, excision plus node dissection, excision plus perfusion, or excision plus both). The median duration of follow-up observation of living patients is greater than 8 years. The relative risk (RR) in disease-free survival and overall survival in the treatment compared with the observation group was calculated using Cox proportional hazards models. RESULTS: Overall, there was no difference in disease-free survival or overall survival between the two groups. Examination of treatment by stratification interactions and subset analysis did not show any treatment-effect differences based on sex or type of therapy. There was also no difference between groups in disease-free survival based on Breslow's thickness of the primary lesion. Overall, 12% of patients who received vitamin A experienced grade 3 or 4 toxicities. CONCLUSION: Based on the lack of overall survival benefit, further evaluation of vitamin A as adjuvant therapy for melanoma does not appear warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. A. Davies, G. Davey Smith, R. Harbord, G. E. Bekkering, J. A. C. Sterne, R. Beynon, and S. Thomas Nutritional interventions and outcome in patients with cancer or preinvasive lesions: systematic review. J Natl Cancer Inst, July 19, 2006; 98(14): 961 - 973. [Abstract] [Full Text] [PDF]

				E. Richtig, H. P. Soyer, M. Posch, U. Mossbacher, P. Bauer, L. Teban, G. Svolba, I. H. Wolf, P. Fritsch, B. Zelger, et al. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group J. Clin. Oncol., December 1, 2005; 23(34): 8655 - 8663. [Abstract] [Full Text] [PDF]

				E. C. Tibaduiza, J. C. Fleet, R. M. Russell, and N. I. Krinsky Excentric Cleavage Products of {beta}-Carotene Inhibit Estrogen Receptor Positive and Negative Breast Tumor Cell Growth In Vitro and Inhibit Activator Protein-1-Mediated Transcriptional Activation J. Nutr., June 1, 2002; 132(6): 1368 - 1375. [Abstract] [Full Text] [PDF]